216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

Munzone, Elisabetta; Regan, Meredith M.; Cinieri, Saverio; Montagna, Emilia; Orlando, Laura; Shi, R.; Campadelli, E.; Gianni, Luca; Giorgi, U.F.F. De; Bengala, Carmelo; Generali, Daniele; Collovà, Elena; Puglisi, Fabio; Cretella, Elisabetta; Zamagni, Claudio; Chini, C.; Goldhirsch, A.; Colleoni, M

doi:10.1016/j.annonc.2022.07.255

Cited by 7 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Median progression-free survival in the paclitaxel arm was 6.9 months; in the arm receiving metronomic therapy, this was increased to 11.1 months (HR = 0.67; 95 % CI: 0.46-0.96). There were no differences in terms of overall survival [50].…”

Section: Meteora IImentioning

confidence: 77%

“…The recently presented METEORA-II study included patients who had received no more than one chemotherapy and no more than two endocrine therapies for the treatment of advanced HRpos/HER2neg disease [50]. The 140 patients in this study were randomized to receive either weekly paclitaxel, or a metronomic therapy with vinorelbine (days 1, 3, and 5), cyclophosphamide (oral, daily), and capecitabine (daily).…”

Section: Meteora IImentioning

confidence: 99%

See 1 more Smart Citation

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Lüftner¹,

Lux²,

Fehm

et al. 2023

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody–drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody–drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

show abstract

Section: Meteora IImentioning

confidence: 77%

Section: Meteora IImentioning

confidence: 99%

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Lüftner¹,

Lux²,

Fehm

et al. 2023

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Most available data on the utility of metronomic chemotherapy (MCT) in advanced breast cancer (ABC) come from single-arm, phase II clinical trials or retrospective analyses [ 10 , 11 , 12 , 13 , 14 , 15 , 16 ]. The results of a phase III study (METEORA), which were presented recently, demonstrate the superiority of metronomic chemotherapy VEX (VEC) over weekly paclitaxel in terms of PFS and time-to-treatment failure (TTF) endpoints [ 17 ]. The METEORA study has thus established the VEC regimen as a safe and active option of MCT for the treatment of advanced BC.…”

Section: Discussionmentioning

confidence: 99%

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data

Buda-Nowak

Kwinta

Potocki

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Breast cancer, with 2.3 million new cases and 0.7 million deaths every year, represents a great medical challenge worldwide. These numbers confirm that approx. 30% of BC patients will develop an incurable disease requiring life-long, palliative systemic treatment. Endocrine treatment and chemotherapy administered in a sequential fashion are the basic treatment options in advanced ER+/HER2- BC, which is the most common BC type. The palliative, long-term treatment of advanced BC should not only be highly active but also minimally toxic to allow long-term survival with the optimal quality of life. A combination of metronomic chemotherapy (MC) with endocrine treatment (ET) in patients who failed earlier lines of ET represents an interesting and promising option. Methods: The methodology includes retrospective data analyses of pretreated, metastatic ER+/HER2- BC (mBC) patients who were treated with the FulVEC regimen combining fulvestrant and MC (cyclophosphamide, vinorelbine, and capecitabine). Results: Thirty-nine previously treated (median 2 lines 1–9) mBC patients received FulVEC. The median PFS and OS were 8.4 and 21.5 months, respectively. Biochemical responses (CA-15.3 serum marker decline ≥50%) were observed in 48.7%, and any increase in CA-15.3 was observed in 23.1% of patients. The activity of FulVEC was independent of previous treatments with fulvestrant of cytotoxic components of the FulVEC regimen. The treatment was safe and well tolerated. Conclusions: Metronomic chemo-endocrine therapy with FulVEC regimen represents an interesting option and compares favorably with other approaches in patients’ refractory to endocrine treatments. A phase II randomized trial is warranted.

show abstract

“…In die kürzlich vorgestellte METEORA-II-Studie wurden Patientinnen eingeschlossen, die höchstens eine Chemotherapie und nicht mehr als 2 endokrine Therapien zur Behandlung der fortgeschrittenen HRpos/HER2neg Erkrankung erhalten hatten [50]. Die 140 Patientinnen wurden entweder zu einer Therapie mit wöchentlichem Paclitaxel oder zu einer metronomischen Therapie mit Vinorelbin (Tag 1, 3 und 5), Cyclophosphamid (oral, täglich) und Capecitabin (täglich) randomisiert.…”

Section: Meteora IIunclassified

“…Das mediane progressionsfreie Überleben belief sich im Paclitaxel-Arm auf 6,9 Monate und konnte durch die metronomische Therapie auf 11,1 Monate (HR = 0,67; 95 %-KI: 0,46-0,96) verlängert werden. Es zeigten sich keine Unterschiede in Bezug auf das Gesamtüberleben [50].…”

Section: Meteora IIunclassified

Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Lüftner

Lux²,

Fehm

et al. 2023

Senologie - Zeitschrift für Mammadiagnostik und -therapie

View full text Add to dashboard Cite

ZusammenfassungDie in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten resultieren in Ergebnissen, die von aktuellen Studien auf internationalen Kongressen und Fachzeitschriften veröffentlicht werden. In diesem Zusammenhang sind neue Ergebnisse der großen CDK4/6-Inhibitor-Studien verfügbar. Auch werden zunehmend Daten von großen genomischen Studien zu Effektivitäts- und Resistenzmechanismen für Patientinnen, die mit CDK4/6-Inhibitoren behandelt worden sind, veröffentlicht. Basierend auf diesen Ergebnissen sollten nicht zuletzt Studien in Bezug auf Kombinationspartner und Therapiesequenzen geplant werden. Mit Sacituzumab Govitecan ist aufgrund neuester Veröffentlichungen nun ein zweites Antikörper-Medikament-Konjugat vorhanden, das bei hormonrezeptorpositiven (HRpos)/HER2-negativen (HER2neg) Patientinnen einen Gesamtüberlebensvorteil mit sich bringt. Diese Übersichtsarbeit fasst die neuesten Entwicklungen zusammen und ordnet sie in den aktuellen Forschungsstand ein.

show abstract

216MO A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)

Cited by 7 publications

References 0 publications

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer—A Retrospective Analysis of Consecutive Patients Data

Update Mammakarzinom 2022 Teil 6 – Brustkrebs in fortgeschrittenen Krankheitsstadien

Contact Info

Product

Resources

About